[go: up one dir, main page]

HUE036524T2 - Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept - Google Patents

Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept

Info

Publication number
HUE036524T2
HUE036524T2 HUE13838016A HUE13838016A HUE036524T2 HU E036524 T2 HUE036524 T2 HU E036524T2 HU E13838016 A HUE13838016 A HU E13838016A HU E13838016 A HUE13838016 A HU E13838016A HU E036524 T2 HUE036524 T2 HU E036524T2
Authority
HU
Hungary
Prior art keywords
yielded
highly purified
correctly folded
folded etanercept
etanercept
Prior art date
Application number
HUE13838016A
Other languages
English (en)
Inventor
Tsutomu Arakawa
Douglas Farrar
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE036524(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of HUE036524T2 publication Critical patent/HUE036524T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE13838016A 2012-09-11 2013-09-10 Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept HUE036524T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
HUE036524T2 true HUE036524T2 (hu) 2018-07-30

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13838016A HUE036524T2 (hu) 2012-09-11 2013-09-10 Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept

Country Status (33)

Country Link
US (6) US20140072560A1 (hu)
EP (1) EP2895188B1 (hu)
JP (3) JP2015533797A (hu)
KR (2) KR102250937B1 (hu)
CN (2) CN104902914B (hu)
AR (1) AR092532A1 (hu)
AU (2) AU2013315750B9 (hu)
BR (1) BR112015005161A2 (hu)
CA (1) CA2882551A1 (hu)
CL (1) CL2015000572A1 (hu)
CO (1) CO7400876A2 (hu)
CY (1) CY1120062T1 (hu)
DK (1) DK2895188T3 (hu)
DO (1) DOP2015000055A (hu)
EA (1) EA031324B1 (hu)
EC (1) ECSP15014138A (hu)
ES (1) ES2657377T3 (hu)
HR (1) HRP20180182T1 (hu)
HU (1) HUE036524T2 (hu)
IL (2) IL237311B (hu)
IN (1) IN2015KN00452A (hu)
LT (1) LT2895188T (hu)
MX (2) MX360044B (hu)
NO (1) NO2972131T3 (hu)
PE (2) PE20200607A1 (hu)
PL (1) PL2895188T3 (hu)
PT (1) PT2895188T (hu)
RS (1) RS57013B1 (hu)
SG (1) SG11201501460RA (hu)
SI (1) SI2895188T1 (hu)
SM (1) SMT201800163T1 (hu)
TW (2) TWI716649B (hu)
WO (1) WO2014043103A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
AR088381A1 (es) 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con meglumina
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
PE20200607A1 (es) * 2012-09-11 2020-03-10 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
MA40232A (fr) * 2014-06-13 2017-04-19 Lupin Ltd Procédé de purification de la protéine de fusion tnfr:fc
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
AU2015372801B2 (en) * 2014-12-31 2018-12-20 Lg Chem, Ltd. Method for preparing tnfr-fc fusion protein containing target content of impurities
US20180079796A1 (en) 2015-03-13 2018-03-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
EP3377514A1 (en) * 2015-11-18 2018-09-26 Merck Patent GmbH Opposite ph-salt gradients for improved protein separations
WO2017084737A1 (en) * 2015-11-18 2017-05-26 Merck Patent Gmbh Improved protein separation in ion exchange chromatography
PL3472177T3 (pl) * 2016-06-17 2024-11-25 F. Hoffmann-La Roche Ag Oczyszczanie przeciwciał wieloswoistych
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
MX2019011343A (es) * 2017-03-24 2019-11-18 Council Scient Ind Res Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
EP4308148A4 (en) * 2021-03-16 2025-01-29 Kashiv Biosciences Llc NOVEL FORMULATION OF A FUSION PROTEIN
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
EP1586635A1 (de) 1990-06-28 2005-10-19 Hoechst Aktiengesellschaft Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000062790A2 (en) 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1261364A1 (en) 2000-02-10 2002-12-04 Wyeth Method of treating or inhibiting cellular injury or cell death
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
AU2002255600B2 (en) 2001-02-23 2008-01-24 Immunex Corporation Efficient recovery of correctly refolded proteins
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
RS51041B (sr) 2003-02-28 2010-10-31 Ares Trading S.A. Tečne formulacije tbp-1 proteina koji vezuju faktor tumorske nekroze
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
US7276477B2 (en) 2003-08-01 2007-10-02 Amgen Inc. Crystals of etanercept and methods of making thereof
KR100853579B1 (ko) 2003-10-14 2008-08-21 인터뮨, 인크. Ｈｃｖ 복제 억제제로서 거대고리 카르복실산 및아실술폰아미드
AU2005216847B2 (en) * 2004-02-27 2010-04-01 Cytiva Bioprocess R&D Ab A process for the purification of antibodies
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
KR101050585B1 (ko) 2004-03-05 2011-07-19 디에스엠 아이피 어셋츠 비.브이. 연속식 살포 및 교호 접선 흐름에 의한 세포 배양 방법
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
EP1962886B2 (en) 2005-12-20 2022-02-23 Bristol-Myers Squibb Company Stable protein formulations
CN101378782A (zh) 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
KR20080098504A (ko) * 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
EP2024392A2 (en) 2006-03-17 2009-02-18 Biogen Idec MA, Inc. Stabilized polypeptide compositions
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
PE20081179A1 (es) 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
US20080213282A1 (en) 2006-12-21 2008-09-04 Jaby Jacob Formulations
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
MX2009009240A (es) 2007-03-02 2009-09-08 Wyeth Corp Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
MX2009013593A (es) 2007-06-14 2010-01-20 Biogen Idec Inc Formulaciones de anticuerpos.
AU2008334099B2 (en) 2007-11-30 2014-07-24 Abbvie Biotechnology Ltd. Protein formulations and methods of making same
US20110129468A1 (en) 2008-02-29 2011-06-02 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
US9238810B2 (en) * 2008-06-05 2016-01-19 Affibody Ab Polypeptide
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
CN107188960A (zh) 2009-08-07 2017-09-22 Emd密理博公司 从样品的一或多种杂质中纯化靶蛋白的方法
KR20180105258A (ko) 2009-08-11 2018-09-27 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
KR101828623B1 (ko) 2010-04-26 2018-02-12 노파르티스 아게 개선된 세포 배양 배지
ES2684921T3 (es) * 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
US20130150554A1 (en) 2010-08-20 2013-06-13 Wyeth Llc Cell culture of growth factor-free adapted cells
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
KR20130142128A (ko) * 2010-10-11 2013-12-27 애브비 인코포레이티드 단백질의 정제 방법
BR112013026883A2 (pt) 2011-04-20 2021-12-07 Sandoz Ag Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
IL315908A (en) 2011-07-01 2024-11-01 Amgen Inc Mammalian cell culture
BR112013033671B1 (pt) 2011-07-01 2022-10-18 Biogen Ma Inc Composições de polipeptídeo de fusão fc livre de arginina e uso
BR112014000352A2 (pt) * 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
EP2753634B1 (en) * 2011-08-17 2017-11-01 Ares Trading S.A. Method for preparing active form of tnfr-fc fusion protein
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
AR088381A1 (es) * 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con meglumina
EA029193B1 (ru) * 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
PE20200607A1 (es) * 2012-09-11 2020-03-10 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
CA2916836C (en) * 2014-07-31 2017-12-12 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
KR20150056601A (ko) 2015-05-26
PT2895188T (pt) 2018-02-08
PL2895188T3 (pl) 2018-06-29
MX2018012749A (es) 2020-11-12
ES2657377T3 (es) 2018-03-05
KR102250937B1 (ko) 2021-05-12
CA2882551A1 (en) 2014-03-20
DOP2015000055A (es) 2015-04-30
AU2013315750A1 (en) 2015-03-05
IN2015KN00452A (hu) 2015-07-17
TW201803593A (zh) 2018-02-01
AU2018247244A1 (en) 2018-11-01
IL237311B (en) 2019-07-31
SG11201501460RA (en) 2015-04-29
BR112015005161A2 (pt) 2017-07-04
WO2014043103A1 (en) 2014-03-20
HRP20180182T1 (hr) 2018-04-20
MX360044B (es) 2018-10-19
DK2895188T3 (en) 2018-02-26
US10954295B2 (en) 2021-03-23
TWI716649B (zh) 2021-01-21
KR20200085937A (ko) 2020-07-15
IL237311A0 (en) 2015-04-30
US10947306B2 (en) 2021-03-16
US20180037642A1 (en) 2018-02-08
US20190300601A1 (en) 2019-10-03
US20190330325A1 (en) 2019-10-31
EA031324B1 (ru) 2018-12-28
EP2895188B1 (en) 2017-11-15
CO7400876A2 (es) 2015-09-30
US10954293B2 (en) 2021-03-23
JP6913066B2 (ja) 2021-08-04
ECSP15014138A (es) 2016-01-29
US20190300602A1 (en) 2019-10-03
MX2015003090A (es) 2015-07-14
NO2972131T3 (hu) 2018-04-21
IL267452A (en) 2019-08-29
US11001627B2 (en) 2021-05-11
AU2013315750B2 (en) 2018-07-12
CN104902914A (zh) 2015-09-09
CN104902914B (zh) 2019-01-01
TW201425331A (zh) 2014-07-01
IL267452B (en) 2021-05-31
PE20150996A1 (es) 2015-08-01
CN110051823A (zh) 2019-07-26
JP2019038817A (ja) 2019-03-14
EP2895188A4 (en) 2016-05-25
US20190300600A1 (en) 2019-10-03
TWI609877B (zh) 2018-01-01
EA201590542A1 (ru) 2015-07-30
SMT201800163T1 (it) 2018-05-02
SI2895188T1 (en) 2018-05-31
AU2013315750B9 (en) 2018-11-15
KR102133699B1 (ko) 2020-07-14
LT2895188T (lt) 2018-04-10
JP2015533797A (ja) 2015-11-26
RS57013B1 (sr) 2018-05-31
AU2018247244B2 (en) 2020-05-28
PE20200607A1 (es) 2020-03-10
CY1120062T1 (el) 2018-12-12
EP2895188A1 (en) 2015-07-22
JP2021100929A (ja) 2021-07-08
US10954294B2 (en) 2021-03-23
AR092532A1 (es) 2015-04-22
US20140072560A1 (en) 2014-03-13
CL2015000572A1 (es) 2016-02-05

Similar Documents

Publication Publication Date Title
HUE036524T2 (hu) Nagy tisztaságú és kiváló kitermelésû helyesen hajtogatott etanercept
HUS2200034I1 (hu) Glikokonjugációs eljárások és kompozíciók
HUE040111T2 (hu) Vegyületek és alkalmazási eljárásaik
EP2921183A4 (en) AIR CLEANER
HUE054444T2 (hu) Prolinnal lezárt kapcsos peptidek és felhasználásuk
EP2802603A4 (en) REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF
BR112013014475A2 (pt) dilatador nasal
EP2632531A4 (en) NASAL DILATOR
HUE059182T2 (hu) Tápanyag-visszanyerõ rendszerek és eljárások
IL229963A0 (en) Substituted quinolines and their use as medicaments
EP2818054A4 (en) METHOD FOR COOKING STEAM NOODLES AND DEVICE FOR COOKING STEAM NOODLES
EP2937066A4 (en) FACE PLASTER
DK2745744T3 (da) Tilbagefoldet pocketmadras
HUE053623T2 (hu) Vegyületek és azok felhasználása
EP2823035A4 (en) ADHÄSIONSSIGNATUREN
EP2844571A4 (en) Faltflasche
EP2802983A4 (en) ISA BRIDGE WITH RECALL
EP3050877A4 (en) Cyclic amine derivative and pharmaceutical use thereof
DE112013002488T8 (de) Vesikuläre Formulierungen, Kits und Verwendungen
FR3000245B1 (fr) Module d'interface
ES1075514Y (es) Salabre plegable y extensible
FR3000243B1 (fr) Module d'interface
FI9997U1 (fi) Marjojen puhdistuslaite
AU2012901774A0 (en) Vaccine and uses thereof
ES1078377Y (es) Acoplamiento machihembrado y rebordeado entre paneles de conductos autoportantes de aire acondicionado y similares.